More Articles

BiosanaPharma starts phase I trial for omalizumab biosimilar in Australia Biosimilars/Research | Posted 24/05/2019

Dutch biosimilars developer BiosanaPharma announced on 21 February 2019 that it had received permission from the Australian Bellberry Human Research Ethics Committee (HREC) to start a phase I clini...

Adherence to generic versus brand-name statins and associated clinical and economic outcomes Generics/Research | Posted 24/05/2019

Despite evidence supporting the efficacy of statins for the treatment and prevention of cardiovascular disease, a lack of adherence to statin treatment continues to be a major problem. Sicras-Maina...

FDA issues final guidance on interchangeable biologicals Guidelines | Posted 17/05/2019

The US Food and Drug Administration (FDA) announced on 10 May 2019 that it had issued final guidance on the pathway for interchangeable biologicals.

Biosimilars market and opportunities in Europe Reports | Posted 17/05/2019

How the biosimilars market in Europe has changed and what opportunities for biosimilars exist for the near term in the region is being reviewed by Murray Aitken in this article [1].

Canadian organizations collaborate to improve biosimilar adoption in cancer and inflammatory rheumatic and bowel disease Biosimilars/General | Posted 17/05/2019

With a number of biosimilars expected to launch in Canada in 2019 and beyond, Canadian organizations are collaborating to improve biosimilar adoption. Canada lags behind the European Union in terms...

Multi-state lawsuit alleges widespread generic price fixing in the US Generics/General | Posted 17/05/2019

A sweeping lawsuit filed on 10 May 2019 by over 40 US states alleges that a number of major drug companies conspired to inflate the prices of generic drugs by as much as 1,000%.

Adalimumab biosimilar Idacio launched in Germany Biosimilars/News | Posted 17/05/2019

Fresenius Kabi, one of the independently operated business segments of global healthcare group Fresenius, announced on 3 May 2019 that it had launched its adalimumab biosimilar Idacio in Germany.

ASCO/ASH give recommendations for biosimilar ESAs Biosimilars/Research | Posted 17/05/2019

Recommendations for biosimilar erythropoiesis-stimulating agents (ESAs) in the management of cancer-associated anaemia have been issued by the American Society of Clinical Oncology (ASCO) and the A...